UK MHRA has granted Marketing Authorisation to Marksans Pharma’s wholly owned subsidiary, Relonchem, UK for Loratadine 5mg/5ml Oral Solution for the UK markets. The product will be manufactured in its UK facility. Loratadine Oral Solution is indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria in adults and children.
Marksans Pharma together with its subsidiaries operates as an integrated international pharmaceutical company. The company’s business is distribution of pharmaceutical products.